NVTAのニュース
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023 2023/04/26 10:59:00 PR Newswire
SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30…
Why Shares of Invitae Soared on Friday 2023/04/22 01:52:11 The Motley Fool
Ark Innovation CEO Cathie Wood said the stock is undervalued.
Futures Slide In Risk-Off End To Volatile Week 2023/04/21 11:58:00 Zero Hedge
Futures Slide In Risk-Off End To Volatile Week US equity futures extended their recent weakness and traded near the week''s lows in early Friday trading as investors digested the latest corporate updates. Investors now await PMI data later today for further direction on the path for monetary policy. Contracts on the S&P 500 and the Nasdaq 100 drifted -0.2% lower as of 7:15 a.m. ET, as both indexes were set to end the week in negative territory, the Nasdaq underperforming slightly. Treasury yields edged higher, while the dollar advanced against other major currencies with a measure of its strength set for its first weekly gain in six weeks. Iron ore, gold and oil all decline, as the gains from the latest OPEC+ output cut are now all gone: so will OPEC cut again to reverse the slide in the one asset class that unlike stocks, everyone loves to short as a hedge for the coming recession? In premarket trading, Tesla edged higher after the electric-vehicle maker increased prices of its Model S and X vehicles in the United States just two days after cutting prices.
Invitae, CSX And Other Big Stocks Moving Higher In Friday''s Pre-Market Session 2023/04/21 10:39:05 Benzinga
U.S. stock futures traded mixed this morning. Here are some big stocks recording gained in today’s pre-market trading session. Mullen Automotive, Inc. (NASDAQ: MULN ) shares jumped 30.2% to $0.1103 in pre-market trading after dropping around 6% on Thursday. ContextLogic Inc. (NASDAQ: WISH ) gained 21% to $8.69 in pre-market trading after the company announced a $50 million buyback program. Atai Life Sciences N.V. (NASDAQ: ATAI ) gained 8.6% to $2.38 in pre-market trading after gaining around 7% on Thursday. Invitae Corporation (NYSE: … Full story available on Benzinga.com
Invitae Shares Surge On Cathie Wood Comments: Here''s What The Ark Invest CEO Said 2023/04/20 20:58:19 Benzinga
Invitae Corp (NYSE: NVTA ) shares are taking off … Full story available on Benzinga.com
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases 2023/03/22 11:30:00 PR Newswire
The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield''s expertise in drug discovery to address high unmet needs among rare disease patients SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical…
Invitae, Epic team up to simplify access to genetic test results 2023/03/21 16:08:50 Seeking Alpha
Genetics company Invitae (NVTA) said it is collaborating with healthcare software company Epic to streamline genetic testing
Invitae Announces Partnership with Epic to Streamline Genetic Testing 2023/03/21 11:30:00 Invitae
Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. Through Aura, Epic''s specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers'' usual workflows so that it''s easier to use genetic insights to inform treatment decisions. "Genetic testing can inform some of the most important care decisions in patients'' lives, and Invitae is making it more accessible to both patients and providers across the Epic community," said Dave Fuhrmann, senior vice president of research and development at Epic. "Aura will help them do so by further enabling precision medicine at many of the nation''s leading healthcare organizations." "Our use of Aura allows patients and providers to seamlessly access genetic testing that can help identify at-risk individuals, enhance early detection and better
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology 2023/03/16 11:30:00 Kwhen Finance
Our Attention Has Been Attracted to Invitae Corporation (NYSE:NVTA) 2023/03/13 18:08:00 US Post News
Invitae Corporation (NVTA)’s stock has witnessed a price hike of 2.60% from the previous close with its current price standing at $1.45. Its current price is -84.24% under its 52-week high of $9.18 and 6.37% more than its 52-week low of $1.36. Based on the past 30-day period, the stock price is -39.32% below the […]
After The Stock Rose 9.35% Over The Week, Is Invitae Corporation (NYSE: NVTA) Still A Buy? 2023/02/03 13:30:00 Marketing Sentinel
Invitae Corporation (NYSE:NVTA)’s traded shares stood at 19.54 million during the last session, with the company’s beta value hitting 1.86. At the close of trading, the stock’s price was $2.69, to imply an increase of 11.62% or $0.28 in intraday trading. The NVTA share’s 52-week high remains $12.04, putting it -347.58% down since that peak … After The Stock Rose 9.35% Over The Week, Is Invitae Corporation (NYSE: NVTA) Still A Buy? Read More »
AMC, NVTA and OPEN are among pre market gainers 2023/02/02 13:45:52 Seeking Alpha
Tenax Therapeutics (TENX) +145%. ZyVersa Therapeutics (ZVSA) +95% Therapeutics, Inc
Enrapturing stocks: Freight Technologies, Inc. (NASDAQ:FRGT -4.71%), Invitae Corporation (NYSE:NVTA -4.84%) 2023/02/01 11:53:55 Stock Equity
FRGT has seen its SMA50 which is now 39.47%. In looking the SMA 200 we see that the stock has seen a -64.03%. NVTA has seen its SMA50 which is … The post Enrapturing stocks: Freight Technologies, Inc. (NASDAQ:FRGT -4.71%), Invitae Corporation (NYSE:NVTA -4.84%) appeared first on Stocks Equity .
InVitae''s ''Long, Uncertain Path'' Toward Profitability: Analyst Downgrades Biotech 2023/01/31 16:51:18 Benzinga
Shares of Invitae Corp (NYSE: NVTA ) came under pressure on Monday, after gaining more than 24% in January . Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs. The Analyst: Matthew Sykes downgraded the rating for Invitae from Neutral to Sell, while reducing the price … Full story available on Benzinga.com
It would be worthwhile to take a closer look at Invitae Corporation (NVTA) 2023/01/31 13:48:00 US Post News
As of Monday, Invitae Corporation’s (NYSE:NVTA) stock closed at $2.48, down from $2.54 the previous day. While Invitae Corporation has underperformed by -2.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVTA fell by -74.38%, with highs and lows ranging from $12.04 to $1.67, whereas the […]